Lupus: Peptide P140/LupuzorTM effectiveness confirmed

January 25th, 2013 in Arthritis & Rheumatism /

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France.

The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the disease.

Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the peptide.

Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immunosuppressants.

These results are published online in the .

More information: Zimmer R., Scherbarth H.R., Rillo O.L., Gomez-Reino J. and Muller S. Annals of Rheumatic Diseases (doi: 10.1136/annrheumdis-2012-202460)

Provided by CNRS

"Lupus: Peptide P140/LupuzorTM effectiveness confirmed." January 25th, 2013. http://medicalxpress.com/news/2013-01-lupus-peptide-p140lupuzortm-effectiveness.html